文献速递前列腺癌

ARNEO试验最终结果:新辅助地加瑞克联合或不联合阿帕他胺在高危前列腺癌根治术前的前列腺癌随机2期研究

Final Results of the Randomised Phase 2 Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer (ARNEO).
PubMed 文献 · Eur Urol Oncol · 2025-12-29

ARNEO是一项双盲、随机、安慰剂对照2期试验,评估高危前列腺癌患者根治术前3个月新辅助地加瑞克联合阿帕他胺对比地加瑞克联合安慰剂的肿瘤学和生活质量结局。中位随访54个月,两组3年生化复发率无显著差异(24% vs 39%,RR 0.63,95%CI 0.34-1.19,p=0.18),无生化复发生存亦无差异(HR 0.72,95%CI 0.37-1.41,p=0.34)。达到ypT2或标本局限疾病者无生化复发生存显著更长(p≤0.0001),两组生活质量各时间点无差异(p>0.47)。

要点

  • 新辅助DEG+APA对比DEG+PBO未显著改善3年生化复发率或BCR-FS。
  • 达到ypT2或标本局限疾病与显著更长的BCR-FS和MFS相关。
  • 达到最小残留疾病(MRD)未预测更好结局,两组生活质量无差异。

核心结论

  • 中位随访54个月,新辅助DEG+APA与DEG+PBO相比,3年BCR率和BCR-FS无显著差异。
  • 达到MRD未预测更好结局,而ypT2和标本局限疾病与改善的BCR-FS和MFS强烈相关。
  • 两组生活质量在所有时间点保持相似。

研究设计与样本

  • ARNEO为双盲、随机、安慰剂对照2期试验,纳入适合根治术的高危前列腺癌患者。
  • 患者接受3个月新辅助DEG+APA或DEG+PBO,除非发生生化复发否则不给辅助或挽救治疗。
  • 预设次要终点包括睾酮恢复(≥150 ng/ml)、3年内BCR(PSA≥0.2 ng/ml)、BCR-FS和生活质量。

主要发现

  • 3年BCR率:DEG+APA组24% vs DEG+PBO组39%,相对风险0.63(95%CI 0.34-1.19),p=0.18。
  • BCR-FS与治疗分配无关(HR 0.72,95%CI 0.37-1.41,p=0.34),与达到MRD无关(p=0.93)。
  • ypT2或标本局限疾病患者BCR-FS显著更长(p≤0.0001),3年BCR率和MFS结果相似。
  • 中位睾酮(>150 ng/dl)恢复时间两组均为5个月(p=0.36),生活质量各时间点无差异(p>0.47)。

关键数值与推荐

  • 3年BCR率DEG+APA组24% vs DEG+PBO组39%,RR 0.63(95%CI 0.34-1.19),p=0.18。
  • BCR-FS的HR 0.72(95%CI 0.37-1.41),p=0.34。
  • 睾酮恢复(>150 ng/dl)中位时间两组均为5个月,p=0.36。
  • 生活质量各时间点比较p>0.47。

临床怎么用

  • 新辅助DEG+APA未显著改善3年BCR率或BCR-FS,不支持常规使用。
  • 术后病理ypT2或标本局限疾病与更好BCR-FS和MFS相关,可指导预后咨询。
  • 达到MRD不应作为预后改善的替代指标。

局限性

  • ARNEO试验的效能基于主要终点MRD率差异,而非报告的次要终点。
  • 中位随访54个月,更长期肿瘤学结局需进一步随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: High-risk prostate cancer (PCa) carries a substantial risk of recurrence and progression after radical prostatectomy (RP). The ARNEO trial previously showed that apalutamide (APA) plus degarelix (DEG) improved the rates of minimal residual disease (MRD) and organ-confined pathology (ypT2) compared with matching placebo (PBO). This study aims to assess the oncological and quality-of-life outcomes of neoadjuvant DEG + APA compared with DEG + PBO. METHODS: ARNEO was a double-blind, randomised, PBO-controlled phase 2 trial investigating neoadjuvant DEG + APA in high-risk PCa patients eligible for RP. Patients received 3 mo of neoadjuvant DEG + APA or DEG + PBO. No adjuvant or salvage therapy was given unless biochemical recurrence (BCR) occurred. Quality-of-life data were collected at predefined time points. The prespecified secondary endpoints included a between-arm comparison of testosterone recovery (testosterone ≥150 ng/ml), BCR within 3 yr (prostate-specific antigen ≥0.2 ng/ml), BCR-free survival (BCR-FS), and quality of life according to treatment allocation. Quality of life was assessed using the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form, International Index of Erectile Function-5 items, and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 questionnaires. Exploratory analyses included metastasis-free survival (MFS) and the relation of outcomes according to pathological outcomes. KEY FINDINGS AND LIMITATIONS: With a median follow-up of 54 mo, the 3-yr BCR rate was not significantly different between groups (24% with DEG + APA vs 39% with DEG + PBO; relative risk 0.63 [95% confidence interval {CI} 0.34-1.19], p = 0.18). BCR-FS was not associated with treatment allocation (hazard ratio 0.72 [95% CI 0.37-1.41]; p = 0.34) or MRD achieved (p = 0.93). However, BCR-FS was significantly longer in patients with ypT2 or specimen-confined disease (p ≤ 0.0001). Similar outcomes regarding 3-yr BCR rates and MFS were found. The median testosterone (>150 ng/dl) recovery time was 5 mo in both the groups (p = 0.36). Quality-of-life outcomes were not different at each time point (p > 0.47). Importantly, the ARNEO trial was powered for a difference in MRD rates (primary endpoint) and not for the reported secondary endpoints. CONCLUSIONS AND CLINICAL IMPLICATIONS: At 3-yr follow-up, no differences were seen in the 3-yr BCR rate or BCR-FS between patients treated with neoadjuvant DEG + APA and those treated with DEG + PBO. Achieving MRD was not predictive of better outcomes, whereas ypT2 and specimen-confined disease were strongly associated with improved BCR-FS and MFS. Quality of life remained similar between groups at all time points.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Giesen A, Devos G, Tosco L, et al. Final Results of the Randomised Phase 2 Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer (ARNEO). Eur Urol Oncol. 2025. PMID: 41469270. doi:10.1016/j.euo.2025.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。